160 related articles for article (PubMed ID: 20187963)
1. Ovarian cancer classification based on dimensionality reduction for SELDI-TOF data.
Tang KL; Li TH; Xiong WW; Chen K
BMC Bioinformatics; 2010 Feb; 11():109. PubMed ID: 20187963
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data.
Yu JS; Ongarello S; Fiedler R; Chen XW; Toffolo G; Cobelli C; Trajanoski Z
Bioinformatics; 2005 May; 21(10):2200-9. PubMed ID: 15784749
[TBL] [Abstract][Full Text] [Related]
3. Feature selection and nearest centroid classification for protein mass spectrometry.
Levner I
BMC Bioinformatics; 2005 Mar; 6():68. PubMed ID: 15788095
[TBL] [Abstract][Full Text] [Related]
4. Application of SELDI-TOF in N-glycopeptides profiling of the urine from patients with endometrial, ovarian and cervical cancer.
Mu AK; Lim BK; Aminudin N; Hashim OH; Shuib AS
Arch Physiol Biochem; 2016 Jul; 122(3):111-6. PubMed ID: 26849673
[TBL] [Abstract][Full Text] [Related]
5. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
Seibert V; Ebert MP; Buschmann T
Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
[TBL] [Abstract][Full Text] [Related]
6. SELDI-TOF-MS proteomics of breast cancer.
Clarke CH; Buckley JA; Fung ET
Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
[TBL] [Abstract][Full Text] [Related]
7. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
8. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
Solassol J; Marin P; Maudelonde T; Mangé A
Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
10. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
Wang Q; Shen J; Li ZF; Jie JZ; Wang WY; Wang J; Zhang ZT; Li ZX; Yan L; Gu J
BMC Cancer; 2009 Aug; 9():287. PubMed ID: 19689818
[TBL] [Abstract][Full Text] [Related]
11. SELDI-TOF proteomic analysis and cancer detection.
Henderson NA; Steele RJ
Surgeon; 2005 Dec; 3(6):383-90, 422. PubMed ID: 16353858
[TBL] [Abstract][Full Text] [Related]
12. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers.
Cazares LH; Diaz JI; Drake RR; Semmes OJ
Methods Mol Biol; 2008; 428():125-40. PubMed ID: 18287771
[TBL] [Abstract][Full Text] [Related]
13. Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer.
Oh JH; Nandi A; Gurnani P; Knowles L; Schorge J; Rosenblatt KP; Gao JX
J Bioinform Comput Biol; 2006 Dec; 4(6):1159-79. PubMed ID: 17245808
[TBL] [Abstract][Full Text] [Related]
14. A data-mining approach to biomarker identification from protein profiles using discrete stationary wavelet transform.
Montazery-Kordy H; Miran-Baygi MH; Moradi MH
J Zhejiang Univ Sci B; 2008 Nov; 9(11):863-70. PubMed ID: 18988305
[TBL] [Abstract][Full Text] [Related]
15. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
16. Biomarker Signature Discovery from Mass Spectrometry Data.
Kong A; Gupta C; Ferrari M; Agostini M; Bedin C; Bouamrani A; Tasciotti E; Azencott R
IEEE/ACM Trans Comput Biol Bioinform; 2014; 11(4):766-72. PubMed ID: 26356346
[TBL] [Abstract][Full Text] [Related]
17. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
Fung ET; Yip TT; Lomas L; Wang Z; Yip C; Meng XY; Lin S; Zhang F; Zhang Z; Chan DW; Weinberger SR
Int J Cancer; 2005 Jul; 115(5):783-9. PubMed ID: 15704152
[TBL] [Abstract][Full Text] [Related]
18. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
19. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
20. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
Brozkova K; Budinska E; Bouchal P; Hernychova L; Knoflickova D; Valik D; Vyzula R; Vojtesek B; Nenutil R
Breast Cancer Res; 2008; 10(3):R48. PubMed ID: 18510725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
